Pulmonx Co. (NASDAQ:LUNG - Get Free Report) insider Geoffrey Beran Rose sold 4,376 shares of Pulmonx stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $6.18, for a total value of $27,043.68. Following the completion of the transaction, the insider now owns 291,057 shares in the company, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Pulmonx Price Performance
Pulmonx stock opened at $6.53 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The stock's 50 day moving average price is $6.77 and its 200 day moving average price is $6.99.
Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.39 million during the quarter, compared to analysts' expectations of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the previous year, the firm posted ($0.39) earnings per share. Equities analysts anticipate that Pulmonx Co. will post -1.53 EPS for the current year.
Hedge Funds Weigh In On Pulmonx
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in Pulmonx by 4.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company's stock worth $332,000 after purchasing an additional 1,633 shares during the last quarter. Barclays PLC raised its holdings in Pulmonx by 1.8% during the third quarter. Barclays PLC now owns 94,109 shares of the company's stock worth $780,000 after purchasing an additional 1,679 shares during the last quarter. 272 Capital LP acquired a new position in Pulmonx during the third quarter worth $25,000. nVerses Capital LLC acquired a new position in Pulmonx during the third quarter worth $26,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx in the second quarter worth $37,000. 91.04% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, Stifel Nicolaus decreased their price target on Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.67.
Read Our Latest Stock Report on LUNG
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
